ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aclaris Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.48+0.20 (+6.10%)
Close on Oct 19, 2026
- Market cap
- $496.72M
- P/E (TTM)
- –
- Dividend yield
- –
Aclaris Therapeutics, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract Research Segment | – | – | – | $1.99M | $2.15M | $2.33M | $2.54M | $6.35M | $9.82M | $13.19M | $3.04M | $16.33M | – | – |
| Therapeutics Segment | – | – | – | $13.76M | $14.64M | $15.45M | $16.18M | $24.59M | $29.46M | $28.32M | $28.21M | $18.10M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract Research Segment | – | – | – | -$2.40M | -$2.80M | -$3.14M | -$3.43M | -$3.52M | -$3.89M | -$4.26M | -$3.94M | -$3.71M | – |
| Therapeutics Segment | – | – | – | -$132.56M | -$125.13M | -$120.28M | -$120.34M | -$21.43M | -$40.99M | -$56.25M | -$65.56M | -$91.76M | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Licensing | $6.34M | $6.40M | $5.95M | $13.76M | $14.64M | $15.45M | $16.18M | $24.59M | $29.46M | $28.32M | $28.21M | $17.93M | 77.2% | -56.7% |
| Contract research | $1.88M | $1.96M | $1.87M | $1.99M | $2.15M | $2.33M | $2.54M | $2.49M | $2.55M | $2.80M | $3.04M | $3.34M | 22.8% | -12.5% |
By region
From the segment and revenue-disaggregation notes of Aclaris Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.